From: Impact of prescription length supply policy on patient medication adherence in Thailand
Variables | Adjusted odds ratio | 95% CI | P value |
---|---|---|---|
Intervention x Period | 1.94 | 1.80–2.09 | < 0.001 |
Age in group (years) | |||
18–25 | Reference | ||
26–50 | 0.58 | 0.45–0.74 | < 0.001 |
51–75 | 0.88 | 0.69–1.12 | 0.305 |
>75 | 0.97 | 0.76–1.24 | 0.803 |
Gender | |||
Female | Reference | ||
Male | 1.12 | 1.09–1.14 | < 0.001 |
Number of medications prescribed at the index date | |||
>1 | Reference | ||
1 | 3.20 | 3.12–3.29 | < 0.001 |
Has history of hospital admission | 0.86 | 0.84–0.89 | < 0.001 |
Class of medications | |||
Sulfonylurea | 0.19 | 0.18–0.19 | < 0.001 |
Non-sulfonylurea | 0.18 | 0.14–0.23 | < 0.001 |
Metformin | 0.50 | 0.49–0.52 | < 0.001 |
Thiazolidinediones | 0.21 | 0.19–0.22 | < 0.001 |
Alpha-glucosidase inhibitors | 0.36 | 0.34–0.39 | < 0.001 |
DPP-4 inhibitors | 0.42 | 0.39–0.44 | < 0.001 |
SGLT-2 inhibitors | 0.49 | 0.39–0.63 | < 0.001 |
Statins | 0.75 | 0.70–0.79 | < 0.001 |
Comorbidities | Â | Â | Â |
Acute myocardial infarction | 1.14 | 1.06–1.21 | < 0.001 |
Congestive heart failure | 0.82 | 0.78–0.87 | < 0.001 |
Cerebrovascular disease | 0.86 | 0.83–0.89 | < 0.001 |
Dementia | 1.22 | 1.14–1.32 | < 0.001 |
Chronic pulmonary disease | 0.87 | 0.82–0.92 | < 0.001 |
Peptic ulcer disease | 1.19 | 1.05–1.36 | 0.006 |
Mild liver disease | 0.87 | 0.82–0.92 | < 0.001 |
Diabetes without chronic complication | 1.42 | 1.36–1.48 | < 0.001 |
Diabetes with chronic complication | 1.72 | 1.66–1.79 | < 0.001 |
Hemiplegia | 0.65 | 0.52–0.83 | < 0.001 |
Cancer | 0.70 | 0.63–0.78 | < 0.001 |
Solid tumor | 1.44 | 1.06–1.95 | 0.02 |
AIDs | 1.36 | 1.13–1.63 | < 0.001 |
CCI score | Â | Â | Â |
0 | Reference | ||
1 | 1.18 | 1.15–1.22 | < 0.001 |
>2 | 1.23 | 1.18–1.29 | < 0.001 |